Candel Therapeutics (CADL) Depreciation & Amortization (CF) (2020 - 2025)

Candel Therapeutics' Depreciation & Amortization (CF) history spans 4 years, with the latest figure at $300000.0 for Q4 2023.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 68.54% to $300000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $966000.0, a 32.33% increase, with the full-year FY2025 number at $800000.0, down 20.0% from a year prior.
  • Depreciation & Amortization (CF) hit $300000.0 in Q4 2023 for Candel Therapeutics, up from $200000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for CADL hit a ceiling of $300000.0 in Q4 2023 and a floor of $6000.0 in Q4 2020.
  • Historically, Depreciation & Amortization (CF) has averaged $141357.1 across 4 years, with a median of $178000.0 in 2021.
  • The widest YoY moves for Depreciation & Amortization (CF): up 2866.67% in 2021, down 53.33% in 2021.
  • Tracing CADL's Depreciation & Amortization (CF) over 4 years: stood at $6000.0 in 2020, then surged by 2866.67% to $178000.0 in 2021, then changed by 0.0% to $178000.0 in 2022, then soared by 68.54% to $300000.0 in 2023.
  • Business Quant data shows Depreciation & Amortization (CF) for CADL at $300000.0 in Q4 2023, $200000.0 in Q3 2023, and $236000.0 in Q2 2023.